Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
By M. Flather, M. Shibata, AndrewJ. S. Coats, D. V. van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, Dan Lucian Dumitrascu, R. Ferrari, P. Lechat and 8 more. European Heart Journal, 2005
1,616 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/eab7a08e26a1375686bd432cf2525e618369af9d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- T. Horwich
- Jeroen J. Bax
- Helmut Baumgartner
- Paulus Kirchhof
- Gerasimos Filippatos
- Frank Flachskampf
- Volkmar Falk
Citations in the corpus
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, positive): “Treatment with nebivolol resulted in an RRR of 14% in the primary composite end-point of death or hospital admission for a cardiovascular reason.(105) † The findings of these trials were also supported by an earlier programme of studies with carvedilol (US carvedilol studies), meta-analysis of other”